Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.63 |
| ▸ | ACHE | P22303 | 8/20 | 0.62 |
| ▸ | BACE1 | P56817 | 8/20 | 0.62 |
| ▸ | AURKA | O14965 | 4/20 | 0.61 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.57 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762522 | 1.00 | ENPP1 (0.63) | ENPP1ACHEBACE1AURKATLR9 | |
| SCHEMBL23726809 | 0.89 | ACHE (0.61) | ENPP1ACHEBACE1AURKATLR9 | |
| SCHEMBL25656146 | 0.86 | ENPP1 (0.46) | ENPP1ACHEBACE1AURKATLR9 | |
| SCHEMBL23727018 | 0.86 | ENPP1 (0.69) | ENPP1ACHEBACE1AURKATLR9 | |
| SCHEMBL30080162 | 0.86 | ENPP1 (0.69) | ENPP1ACHEBACE1AURKATLR9 | |
| SCHEMBL23762309 | 0.84 | ENPP1 (0.72) | ENPP1ACHEBACE1AURKATLR9 | |
| SCHEMBL25679271 | 0.82 | ACHE (0.74) | ENPP1ACHEBACE1AURKATLR9 | |
| Hydrochloric Acid SCHEMBL31531469 | 0.81 | ENPP1 (0.73) | ENPP1ACHEBACE1AURKATLR9 | |
| SCHEMBL3873291 | 0.80 | ACHE (0.78) | ENPP1ACHEBACE1AURKAPDE10A | |
| SCHEMBL11882354 | 0.80 | ACHE (0.88) | ENPP1ACHEBACE1AURKAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-115362145-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4100394-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115362145-A | Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885ACHE 939/4885BACE1 1502/4885 |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | ENPP1 1/4885ACHE 939/4885BACE1 1502/4885 |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | ENPP1 1/4885ACHE 721/4885BACE1 896/4885 |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | ENPP1 1/4885ACHE 939/4885BACE1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.